Remaining lease term Operating Lease Remaining Term Operating Lease Remaining Term Stock to be purchased by common stock warrants (in shares) Shares of Common Stock to be Purchased by Common Stock Warrants Shares of Common Stock to be Purchased by Common Stock Warrants Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Pending claim Loss Contingency, Pending Claims, Number Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Unvested share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Class of warrant or right, warrants exercised (in shares) Class of Warrant or Right, Warrants Exercised The number of class of warrant or right exercised. 2023 Long-Term Debt, Maturity, Year Two Debt Instrument [Axis] Debt Instrument [Axis] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Property and equipment, gross Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Royalty Obligation Activity Royalty Obligation Activity [Table Text Block] Royalty Obligation Activity Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Other income (expenses): Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital At The Market Offering At The Market Offering [Member] At The Market Offering Computer, network equipment and software Computer, Network Equipment and Software [Member] Assets which are related to computer, network equipment and software. Statistical Measurement [Domain] Statistical Measurement [Domain] Discount rate Lessee, Operating Lease, Discount Rate Depreciation and amortization Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Proceeds from issuance of debt Proceeds from Issuance of Debt Interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Proceeds from issuance of common stock under public equity offering, warrants and warrant exercises, net Proceeds From Issuance Of Public Offering, Issuance Of Warrants and Warrant Exercises Proceeds From Issuance Of Public Offering, Issuance Of Warrants and Warrant Exercises Elective redemption percentage of debt Elective redemption percentage of debt Elective redemption percentage of debt. Domestic Tax Authority Domestic Tax Authority [Member] Retirement of debt Repayments of Debt Other, net Other Noncash Income (Expense) Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants Accounts receivable Accounts Receivable, before Allowance for Credit Loss Senior Secured Notes Due 2025 - First Additional Offering First Additional Offering [Member] The first additional offering of the loan agreement. Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Dilutive securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Debt Maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Eighth Month Eighth Month [Member] Eighth Month Contract and other receivables Other Receivables, Gross, Current Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 2028-2033 Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Repurchase price percentage Debt Instrument, Redemption Price, Percentage Offering period term Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Plan Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Plan Offering Period Assets, fair value disclosure Assets, Fair Value Disclosure Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Right-of-Use Assets and Lease Obligations Lessee, Operating Leases [Text Block] Research and development, costs capitalized Research and Development, Costs Capitalized Research and Development, Costs Capitalized Payments of financing costs Payments of Financing Costs Liability related to the sale of future revenue, net at December 31, 2021 Liability related to the sale of future revenue, net (includes current portion of $1,147) Liabilities, Sale of Future Royalties Liabilities, Sale of Future Royalties Premium on early retirement of debt Premiums Paid, Early Retirement of Debt Premiums Paid, Early Retirement of Debt Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Summary of Restricted Stock Units Nonvested Restricted Stock Shares Activity [Table Text Block] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Key Employees Executive Officer [Member] Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Private equity Private equity [Member] Private equity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Warrants issued to purchase common stock (in shares) Class Of Warrant Or Right Warrants Issued During Period The number of warrants issued during the period. Net proceeds after placement agent fees, expenses, and offering expenses payable Net Proceeds After Placement Agent Fees, Expenses, and Offering Expenses Payable Net Proceeds After Placement Agent Fees, Expenses, and Offering Expenses Payable Employee Stock Purchase Plan Employee Stock [Member] Weighted average remaining contract life Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Additions Asset Retirement Obligation, Liabilities Incurred Trade receivables and other receivables, net Increase (Decrease) in Accounts and Other Receivables Award Type [Axis] Award Type [Axis] Automatic renewal period of agreement Automatic Renewal Period of Agreement Period for which the agreement is renewed automatically. Net cash used for operating activities Net Cash Provided by (Used in) Operating Activities Lease liabilities, current Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] 2022 Accounts Receivable Allowances, Provision Related to Sales For an unclassified balance sheet, a valuation of sales allowance for receivables related to sales due a company that are expected to be uncollectible. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Intangible Assets, Net and Other Assets [Abstract] Intangible Assets, Net and Other Assets [Abstract] Fair value of warrants issued Adjustments to Additional Paid in Capital, Fair Value of Warrants Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of fair value of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Document Annual Report Document Annual Report Beginning Balance Ending balance Accounts Receivable Allowances and Accruals For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible and accruals. Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Permanent differences Effective Income Tax Rate Reconciliation, Permanent Differences, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to permanent differences. Revenues and Trade Receivables, Net Revenues and Trade Receivables, Net [Text Block] The entire disclosure of revenues and trade receivables, net. Number of $1,000 annual minimum guaranteed royalties Number Of $1,000 Annual Minimum Guaranteed Royalties Number Of $1,000 Annual Minimum Guaranteed Royalties Common stock issued under equity offering Stock Issued During Period, Value, New Issues Purchased intangible Technology-Based Intangible Assets [Member] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 2020 Additional Notes 2020 Additional Notes [Member] 2020 Additional Notes Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Commercial Exploitation Agreement with Indivior Commercial Exploitation Agreement with Indivior [Member] The commercial exploitation agreement with Indivior. Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Useful Lives Property, Plant and Equipment, Useful Life Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Forfeited and Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Severance costs Severance Costs Unvested, balance at beginning of period (in dollars per share) Unvested, balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value 12.5% Senior Secured Notes and Loans Payable Debt Disclosure [Text Block] Proceeds from common stock issued under private equity offering, net Proceeds from Issuance Private Offering Proceeds from Issuance Private Offering Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred revenue Increase (Decrease) in Deferred Revenue Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Income Tax Disclosure [Table] Income Tax Disclosure [Table] Disclosure of information about income taxes. 2024 Long-Term Debt, Maturity, Year Three Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Subsequent Event Subsequent Event [Member] Revenue Revenue Benchmark [Member] Document Period End Date Document Period End Date Put Option Put Option [Member] First Seven Months First Seven Months [Member] First Seven Months Proprietary product sales, net Proprietary Product Sales [Member] The aggregate revenue generated from proprietary product sales. Number of uncertain tax positions Number of Uncertain Tax Positions Number of Uncertain Tax Positions Pro rata portion of target bonus Pro Rata Portion of Target Bonus Pro Rata Portion of Target Bonus Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Trade Accounts Receivable Accounts Receivable [Policy Text Block] Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Income Statement Location [Axis] Income Statement Location [Axis] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Antidilutive Securities [Axis] Antidilutive Securities [Axis] License and royalty revenue License and Royalty Revenue [Member] The aggregate revenue generated from licensing and royalties. Accrued expenses Total accrued expenses Accrued Liabilities, Current Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Interest income and other income, net Interest and Other Income Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Fair value Long-Term Debt, Fair Value Accounting Policies [Abstract] Accounting Policies [Abstract] Manufacture and supply revenue Manufacture and Supply Revenue [Member] The aggregate revenue generated from manufacture and supply. Agreement term (in months) Agreement Term Agreement Term Accrued compensation Employee-related Liabilities, Current Variable lease expense Variable Lease, Cost Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Number of yearly offering periods Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Offering Periods Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Offering Periods Amortization of debt issuance costs and discounts Amortization of Debt Issuance Costs and Discounts Net Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Summary of Stock Option Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 481(a) adjustment Deferred Tax Liabilities, 481(a) Adjustment Deferred Tax Liabilities, 481(a) Adjustment Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Weighted average recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Loss on the extinguishment of debt Loss on the extinguishment of debt Gain (Loss) on Extinguishment of Debt Percentage of cash proceeds Repurchase Offer, Percentage of Cash Proceeds Received Repurchase Offer, Percentage of Cash Proceeds Received Schedule of Finite Lived - Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Liability for Asset Retirement Obligations Schedule of Asset Retirement Obligations [Table Text Block] Finished goods Inventory, Finished Goods, Gross Basis of Presentation and Principles of Consolidation Basis of Accounting [Text Block] Entity Registrant Name Entity Registrant Name Common stock issued under equity offering (in shares) Stock Issued During Period, Shares, New Issues Research and development project duration Research and Development Project Duration Research and Development Project Duration Subsequent Events Subsequent Events [Text Block] Consulting fee Consulting Fee Consulting Fee Intangible Assets, Net and Other non-current assets Intangible Assets, Net and Other Assets Disclosure [Text Block] The entire disclosure for intangible assets and other assets. Interest expense related to the sale of future revenue Interest Expense, Sale of Future Revenues Interest Expense, Sale of Future Revenues Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Minimum royalty receivable Minimum Annual Royalty Receivable Minimum Annual Royalty Receivable Purchased patent Patents [Member] Entity Address, City or Town Entity Address, City or Town Employee Benefit Plans Retirement Benefits [Text Block] Interest expense related to the sale of future revenue Interest Expense, Sale of Future Revenues (Excluding Amortization) Interest Expense, Sale of Future Revenues (Excluding Amortization) Leases [Abstract] Revenues and Trade Receivables, Net [Abstract] Revenues and Trade Receivables, Net [Abstract] Costs and expenses: Operating Expenses [Abstract] NOL carryforwards Deferred Tax Assets, Operating Loss Carryforwards Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Royalty Royalty [Member] Common stock, par or stated value per share (in dollars per share) Common Stock, Par or Stated Value Per Share License & Supply Agreement License & Supply Agreement [Member] License & Supply Agreement Suboxone Agreements Settlement Suboxone Agreements Settlement [Member] Suboxone Agreements Settlement Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Share price (in dollars per share) Share Price Operating loss carryforwards Operating Loss Carryforwards Trading Symbol Trading Symbol Entity File Number Entity File Number Warrants Warrants Disclosure [Text Block] The entire disclosure for warrants. Research & development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Senior Secured Notes Due 2025 - Second Additional Offering Second Additional Offering [Member] The second additional offering of the loan agreement. Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Weighted average remaining contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Title of Individual [Axis] Title of Individual [Axis] Supplemental Agreement with Indivior Supplemental Agreement with Indivior [Member] The supplemental commercial exploitation agreement with Indivior. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units Restricted Stock Units (RSUs) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Loans Payable Proceeds from (Repayments of) Notes Payable Vested or expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Sale of Future Revenue [Roll Forward] Sale of Future Revenue [Roll Forward] Sale of Future Revenue Raw material Inventory, Raw Materials, Gross Accounts payable Increase (Decrease) in Accounts Payable Company Overview and Equity Transactions Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Common Stock issued upon warrant exercises Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Revenues Revenues Revenues Concentrations of risk Concentration Risk, Percentage Subsequent Events [Abstract] Right to sell common stock, value Right to Sell Common Stock, Value Right to Sell Common Stock, Value License agreement term License Agreement Term License agreement term period. Income Taxes Income Tax Disclosure [Text Block] Number of licensed commercialized products Number Of Licensed Commercialized Products Number Of Licensed Commercialized Products Premium paid to retire debt Consent fee payment Payment for Debt Extinguishment or Debt Prepayment Cost Notice period of intent not to renew agreement Notice Period for Not to Renew Agreement Notice period of intent not to renew agreement, prior to the expiration of the initial or renewal term. Credit Facility [Domain] Credit Facility [Domain] Audit Information [Abstract] Audit Information Amortization expense Amortization of Intangible Assets Exercise price of warrants (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash payments for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Net loss per share - basic (in usd per share) Earnings Per Share, Basic Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Number of quarterly payments Debt Instrument, Principal, Number Of Quarterly Payments Debt Instrument, Principal, Number Of Quarterly Payments Credits and payments Accounts Receivable Allowances, Credits and payments For an unclassified balance sheet, a valuation of sales allowance for receivables related to credits due a company that are expected to be uncollectible. Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Research and development, amortization period (in years) Research And Development, Amortization Period Research And Development, Amortization Period Total stockholders’ deficit Beginning balance Ending balance Stockholders' Equity Attributable to Parent Director Director [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Marathon Pangolin Royalty LLC Marathon Pangolin Royalty LLC [Member] Marathon Pangolin Royalty LLC Orphan Drug and R&D Tax Credits Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Entity Interactive Data Current Entity Interactive Data Current Number of leases Number of Leases Number of Leases Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other Other Assets, Miscellaneous, Noncurrent Accumulated Deficit Retained Earnings [Member] Common Stock Common Stock [Member] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Income Taxes Income Tax, Policy [Policy Text Block] License Agreement with Sunovion Pharmaceuticals, Inc. Upfront License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member] The license agreement made with sunovion pharmaceuticals, inc. advance payments. Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective annual interest rate Debt Instrument, Interest Rate, Effective Percentage Issuance [Axis] Issuance [Axis] Issuance Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Senior Secured Notes Due 2025 Senior Secured Notes Due 2025 Twelve Point Five, Senior Secured Notes due June 30, 2025 [Member] A debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer. Lease liabilities Operating Lease, Liability, Noncurrent Section 174 R&D Capitalization Deferred Tax Assets, Tax Credit Carryforwards, Research Cardinal Cardinal [Member] Cardinal Statistical Measurement [Axis] Statistical Measurement [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Leasehold improvements Leasehold Improvements [Member] Interest limitation imposed by the TJCA Tax Cuts and Jobs Act of 2017, Deferred Tax Assets, Interest Limitation Amount of interest limitation for remeasurement of deferred tax asset from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017. Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Lincoln Park Agreement Lincoln Park Agreement [Member] Lincoln Park Agreement Equity Components [Axis] Equity Components [Axis] Litigation Case [Domain] Litigation Case [Domain] Segment Information Segment Reporting, Policy [Policy Text Block] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Vested restricted stock units APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Unvested, at beginning of period (in shares) Unvested, at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Intangible assets, gross Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Milestone payment, no longer receivable Milestone Payment, No Longer Receivable Milestone Payment, No Longer Receivable Right-of-use assets, net Operating Lease, Right-of-Use Asset Asset Retirement Obligation Disclosure [Abstract] Asset Retirement Obligation Disclosure [Abstract] Unusual Risk or Uncertainty [Line Items] Unusual Risk or Uncertainty [Line Items] 2022 Equity Inducement Plan 2022 Equity Inducement Plan [Member] 2022 Equity Inducement Plan Deferred revenue, revenue recognized Deferred Revenue, Revenue Recognized Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Vested or expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Foreign Tax Authority Foreign Tax Authority [Member] Local Phone Number Local Phone Number Number of transactions Number Of Transactions Number Of Transactions Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventory Deferred Tax Assets, Inventory Inventories Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Stock Compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets State and Local Jurisdiction State and Local Jurisdiction [Member] Accrued debt fees Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Licensing and Supply Agreement with Pharmanovia Licensing and Supply Agreement with Pharmanovia [Member] Licensing and Supply Agreement with Pharmanovia Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Liability related to the sale of future revenue, net Liabilities, Sale of Future Revenue, Net Liabilities, Sale of Future Revenue, Net Trade and other receivables, net Trade and other receivables, net Trade and other receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables). Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Liabilities, fair value disclosure Liabilities, Fair Value Disclosure Manufacture and supply Manufacturing and supply [Member] Primary financial statement caption encompassing Manufacturing and supply expense. Adjustments to reconcile net loss to net cash used for operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Valuation Allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Number of shares reserved for issuance (in shares) Number of Shares Reserved for Issuance The number of shares which are reserved for issuance. 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Contract with customer, receivable, after allowance for credit loss Contract with Customer, Receivable, after Allowance for Credit Loss Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Patent Litigation Settlement With BioDelivery Sciences International, Inc Patent Litigation Settlement With BioDelivery Sciences International, Inc [Member] Patent Litigation Settlement With BioDelivery Sciences International, Inc Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Asset retirement obligation Balance at beginning of period Balance at ending of period Asset Retirement Obligation Weighted-average number of common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Risks and Uncertainties Concentration Risk Disclosure [Text Block] Inventory, net Schedule of Inventory, Current [Table Text Block] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Receivables Accounts Receivable [Member] Sale of Future Revenue Sale of Future Revenue [Text Block] Sale of Future Revenue Common stock, $0.001 par value. Authorized 250,000,000 shares; 54,827,734 and 41,228,736 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Packaging material Inventory Packing Material Gross Amount of packaging materials expected to be sold within one year or operating cycle, if longer. Senior Notes Senior Notes [Member] Cash payment representing 90 days of base pay Cash Payment Representing 90 Days of Base Pay Cash Payment Representing 90 Days of Base Pay Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Cash and cash equivalents Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Issuance [Domain] Issuance [Domain] Issuance [Domain] Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted average remaining contractual term, vested or expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Concentration Risk [Line Items] Concentration Risk [Line Items] Haisco Pharmaceutical Group Co., Ltd, Upfront Payment Haisco Pharmaceutical Group Co., Ltd, Upfront Payment [Member] Haisco Pharmaceutical Group Co., Ltd, Upfront Payment Deferred revenue Contract with Customer, Liability, Current Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Income Statement Location [Domain] Income Statement Location [Domain] Duration of payment [Axis] Duration of payment [Axis] Duration of payment Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Lease cost Operating Lease, Cost Principal amount Debt Instrument, Face Amount Shares issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Commitment shares issued (in shares) Commitment Shares, Stock Issued During Period, Shares, New Issues Commitment Shares, Stock Issued During Period, Shares, New Issues Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Humana Inc. v. Aquestive Therapeutics, Inc. Humana Inc. v. Aquestive Therapeutics, Inc. [Member] Humana Inc. v. Aquestive Therapeutics, Inc. Deferred tax assets: Components of Deferred Tax Assets [Abstract] Other non-current assets Total other non-current assets Other Assets, Noncurrent Weighted Average Remaining Contractual Term in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Employee stock purchase plan, purchase price percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Net proceeds from issuance of initial notes, warrants and first offer rights Net Proceeds from Issuance of Initial Notes, Warrants and First Offer Rights The net cash inflow associated with the amount received from issuance of initial notes, warrants and first offer rights. Income taxes at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Shares issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Unamortized deferred debt issuance cost and deferred debt discounts Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Accrued distribution expenses Accrued Marketing Costs, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code State income tax Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Material Agreements [Abstract] Material Agreements [Abstract] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Cash and cash equivalents: Cash and Cash Equivalents [Abstract] Stock Options Share-Based Payment Arrangement, Option [Member] Duration of payment [Domain] Duration of payment [Domain] Duration of payment [Domain] Title of Individual [Domain] Title of Individual [Domain] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Total Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accounts receivable Deferred Tax Assets, Accounts Receivable Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accounts receivable. Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Return to provision Effective Income Tax Rate Reconciliation, Tax Credit, Return to Provision, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision tax credit. Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total costs and expenses Operating Expenses Maximum Maximum [Member] Contingent consideration, milestone payments Contingent Consideration, Milestone Payments Contingent Consideration, Milestone Payments Summary of Revenue Revenue from External Customers by Products and Services [Table Text Block] Total current assets Assets, Current Real estate and personal property taxes Taxes Payable, Current Other Non-Current Liabilities Asset Retirement Obligation Disclosure [Text Block] Entity Small Business Entity Small Business License Agreement with Sunovion Pharmaceuticals, Inc. License Agreement with Sunovion Pharmaceuticals, Inc. [Member] The license agreement made with sunovion pharmaceuticals, inc. Balance (in shares) Balance (in shares) Shares, Outstanding Intangible assets, net Intangible assets, net Finite-Lived Intangible Assets, Net Warrants and Rights Note Disclosure [Abstract] Warrants and Rights Note Disclosure [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Common stock issued upon warrant exercises (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Royalty receivable Royalty Receivable Royalty Receivable Remaining amount available for offering Sale Of Stock, Remaining Amount Available For Offering Sale Of Stock, Remaining Amount Available For Offering Payables and Accruals [Abstract] Payables and Accruals [Abstract] Number of states that brought a lawsuit Number Of States That Brought A Lawsuit Number Of States That Brought A Lawsuit Subsequent Event [Line Items] Subsequent Event [Line Items] Grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants, Grant Date Fair Value The fair market value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date. Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Stock [Line Items] Class of Stock [Line Items] Vested restricted stock units (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total operating lease liabilities Operating Lease, Liability Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Officer Officer [Member] Co-development and research fees Co-Development and Research Fees [Member] The aggregate revenue generated from Co-development and research fees. Assertio Holdings, Inc Assertio Holdings, Inc [Member] Assertio Holdings, Inc Liabilities and stockholders’ deficit Liabilities and Equity [Abstract] Neurelis, Inc. v. Aquestive Therapeutics, Inc. Neurelis, Inc. v. Aquestive Therapeutics, Inc. [Member] Neurelis, Inc. v. Aquestive Therapeutics, Inc. Granted (in dollars per share) Exercise prices (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Additions to intangible assets Payments to Acquire Intangible Assets Forfeited and Expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Consideration received on sale of stock Sale of Stock, Consideration Received on Transaction Inventories, net Total inventory Inventory, Net Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Auditor Location Auditor Location Warrant Warrant [Member] Equity Distribution Agreement Equity Distribution Agreement [Member] Equity Distribution Agreement Entity Filer Category Entity Filer Category Weighted-average number of common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Unusual Risk or Uncertainty [Table] Unusual Risk or Uncertainty [Table] Total share-based compensation expenses Share-Based Payment Arrangement, Expense Contingencies (Note 20) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Selling, general and administrative General and Administrative Expense [Member] Revenues Royalties related to the sale of future revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Payments of loan costs Payments of Loan Costs Common stock entitled to purchasers by pre-funded warrants (in shares) Shares of Common Stock Entitled to Purchasers by Pre-funded Warrants Shares of Common Stock Entitled to Purchasers by Pre-funded Warrants Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Entity Voluntary Filers Entity Voluntary Filers Depreciation, amortization, and impairment Depreciation, Depletion and Amortization, Nonproduction Share-Based Compensation Share-Based Payment Arrangement [Text Block] Allowance for doubtful accounts Less: allowance for bad debt Accounts Receivable, Allowance for Credit Loss Summary of Share-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Liability Related to the Sale of Future Revenue Sale of Future Revenue [Policy Text Block] Sale of Future Revenue Severance period (in months) Severance Period Severance Period Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Common Stock Warrants Common Stock Warrants [Member] Common Stock Warrants Payments for taxes on share-based compensation Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ deficit Liabilities and Equity Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Proceeds from shares issued under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Amortization of issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Proceeds from sale of future revenue Proceeds From Sale of Future Revenues, Net Proceeds From Sale of Future Revenues, Net Trade receivables, period for credit term Credit Term of Trade Receivables Term of trade receivables depending on the customer and type of invoice in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Ex-United States Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred tax assets Deferred Tax Assets, Gross Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions. Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net loss per share - diluted (in usd per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Debt instrument, amount redeemed Debt Instrument, Amount Redeemed Debt Instrument, Amount Redeemed Number of installments Number Of Installments Number Of Installments Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Accretion Asset Retirement Obligation, Accretion Expense Payments of stock issuance costs Payments of Stock Issuance Costs Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Monetization Agreement Monetization Agreement [Member] Monetization Agreement Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Summary of Accounts Receivable, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Customer Concentration Risk Customer Concentration Risk [Member] Unrecognized tax benefits Unrecognized Tax Benefits Net deferred tax asset/(liability) Deferred Tax Assets, Net of Valuation Allowance Ninth through Eighteenth Month Ninth through Eighteenth Month [Member] Ninth through Eighteenth Month Entity Ex Transition Period Entity Ex Transition Period License Agreement with Sunovion Pharmaceuticals, Inc Milestones License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] The license agreement made with sunovion pharmaceuticals, inc. milestones. Term of award Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Days of base pay Days of Base Pay Days of Base Pay Schedule of Operating Lease Liabilities Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Sale of Future Revenue Deferred Tax Assets, Sale Of Future Revenue Deferred Tax Assets, Sale Of Future Revenue Less: sales-related allowances Accounts Receivable Allowances and Accruals - Trade and Other Receivables, Net For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible, classified within trade and other receivables, net. Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Coverage duration Coverage duration Coverage duration Product and Service [Axis] Product and Service [Axis] Liability related to the sale of future revenue, current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Cost of common stock issued under equity offering Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs State rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Interest expense Interest Expense Intrinsic value, exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Ownership limitation, maximum percent of beneficial ownership Ownership Limitation, Maximum Percent Of Beneficial Ownership Ownership Limitation, Maximum Percent Of Beneficial Ownership Credit Facility [Axis] Credit Facility [Axis] Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Inventory Inventory Disclosure [Text Block] Machinery Machinery and Equipment [Member] Subsequent Event [Table] Subsequent Event [Table] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Proceeds from debt, contingent on additional milestones Contingent Monetization Agreement, Milestone Payment Contingent Monetization Agreement, Milestone Payment Entity Tax Identification Number Entity Tax Identification Number At The Market Offering, Amendment One At The Market Offering, Amendment One [Member] At The Market Offering, Amendment One CLA KemPharm CLA KemPharm [Member] CLA KemPharm Exercise of stock options (in shares) Stock Issued During Period, Shares, Exercise of Stock Options Stock Issued During Period, Shares, Exercise of Stock Options Atnahs Pharma UK Limited Atnahs Pharma UK Limited [Member] Atnahs Pharma UK Limited Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Deferred tax liabilities Deferred Tax Liabilities, Gross Additional borrowing capacity Debt Instrument Additional Borrowing Capacity Amount of debt that can be borrowed in addition to initial notes. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Current portion of liability related to sale of future revenue Liabilities, Sale of Future Royalties, Current Liabilities, Sale of Future Royalties, Current Manufacture and supply Manufacture and Supply Costs The aggregate costs incurred in the production of goods and supply for sale. Schedule of Income Tax Benefit Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Property and equipment Deferred Tax Assets, Property, Plant and Equipment Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Numerator: Undistributed Earnings, Basic [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Material Agreements Collaborative Arrangement Disclosure [Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Other Accrued Liabilities, Current Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Loans payable, current Line of Credit, Current Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Per Share Data Earnings Per Share, Policy [Policy Text Block] 2022 Long-Term Debt, Maturity, Year One Share-based compensation Share-Based Payment Arrangement, Noncash Expense Summary of Sales-related Allowances Schedule of Accounts Receivable Allowances [Table Text Block] Tabular disclosure of valuation of sales allowance for receivables due a company that are expected to be uncollectible including a rollforward of the balance. Exercise of stock options APIC, Share-based Payment Arrangement, Exercise of Stock Options APIC, Share-based Payment Arrangement, Exercise of Stock Options Other non-current liabilities Other Liabilities, Noncurrent Loans payable, net Loans Payable, Noncurrent Intrinsic value, vested or expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested or expected to Vest, Aggregate Intrinsic Value The aggregate intrinsic value of options vested or expected to vest. Capital expenditures Payments to Acquire Property, Plant, and Equipment Sale of stock, aggregate offering price Sale of Stock, Aggregate Offering Price Sale of Stock, Aggregate Offering Price Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Proceeds from collaborators Proceeds from Collaborators Estimated amortization expense Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Depreciation expense related to ARO Asset Retirement Obligations Depreciation Expense Depreciation expense of asset retirement obligation. Customer [Domain] Customer [Domain]